Corvus Pharmaceuticals (CRVS) Equity Average (2016 - 2026)
Corvus Pharmaceuticals' Equity Average history spans 11 years, with the latest figure at $150.9 million for Q1 2026.
- Quarterly Equity Average rose 268.63% to $150.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $150.9 million through Mar 2026, up 268.63% year-over-year, with the annual reading at $46.9 million for FY2025, 31.61% up from the prior year.
- Equity Average came in at $150.9 million for Q1 2026, up from $66.5 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $150.9 million in Q1 2026 to a low of $22.5 million in Q4 2024.
- The 5-year median for Equity Average is $52.5 million (2023), against an average of $60.8 million.
- Year-over-year, Equity Average crashed 45.79% in 2024 and then skyrocketed 268.63% in 2026.
- Corvus Pharmaceuticals' Equity Average stood at $60.4 million in 2022, then crashed by 31.31% to $41.5 million in 2023, then plummeted by 45.79% to $22.5 million in 2024, then surged by 195.65% to $66.5 million in 2025, then soared by 127.03% to $150.9 million in 2026.
- Per Business Quant, the three most recent readings for CRVS's Equity Average are $150.9 million (Q1 2026), $66.5 million (Q4 2025), and $76.0 million (Q3 2025).